Correlation Engine 2.0
Clear Search sequence regions

  • child (1)
  • children (1)
  • dabigatran (8)
  • direct (1)
  • humans (1)
  • minor (1)
  • patients (5)
  • phase (3)
  • switzerland (1)
  • vitamin k (1)
  • Sizes of these terms reflect their relevance to your search.

    Although rare in children, venous thromboembolism (VTE) is markedly more likely in hospitalized patients, particularly with the use of central venous access devices. Dabigatran etexilate (Pradaxa®) is one of the first direct non-vitamin K antagonist oral anticoagulants (DOAC) approved for use in pediatric patients. It is approved in the EU and USA for the treatment of VTE in patients who have been treated with a parenteral anticoagulant for ≥ 5 days, and for the prevention of recurrent VTE. In an open-label, phase 2b/3 clinical trial in pediatric patients with acute VTE treated for ≈ 3 months, dabigatran etexilate was non-inferior to standard of care (SOC) treatment for the primary composite endpoint of complete thrombus resolution, freedom from recurrent VTE and VTE-related death. In a single-arm phase 3 safety study, few patients experienced recurrent VTE with ≤ 12 months of anticoagulation with dabigatran etexilate. Dabigatran etexilate was generally well tolerated in both studies; bleeding events were mostly minor and, in the phase 2b/3 study, occurred at a similar incidence to SOC. Although further data will be useful, dabigatran etexilate is a valuable and convenient treatment option in pediatric VTE. © 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.


    Julia Paik. Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism. Paediatric drugs. 2022 Jul;24(4):423-431

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 35699915

    View Full Text